Duration of prodromal phase and severity of hemolytic uremic syndrome.
Children
Complications
Escherichia coli
STEC-HUS
Severe disease
Time to diagnosis
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
30
03
2023
accepted:
17
07
2023
revised:
16
07
2023
medline:
27
11
2023
pubmed:
1
8
2023
entrez:
1
8
2023
Statut:
ppublish
Résumé
Some data have recognized an association between shorter prodromal phase and severe episode of Shiga toxin-producing Escherichia coli-related hemolytic uremic syndrome (STEC-HUS). Our aims were to confirm such association and analyze characteristics of STEC-HUS patients according to duration of the prodromal phase. Patients treated from 2000 to 2022 were compared according to the presence of severe (> 10 days of dialysis and/or extra-renal complications) or non-severe disease. Association between prodromal phase duration and disease severity was assessed by ROC curve and by classifying the cohort in 3 groups according to time to diagnosis. Non-severe (n = 145) and severe (n = 71) cases were compared. The latter had shorter prodromal phase, higher leukocyte count, hemoglobin, lactic dehydrogenase, liver enzymes, C-reactive protein, urea and creatinine, and lower albumin and sodium; only prodromal phase duration (p = 0.02) and leukocyte count (p = 0.02) remained significant in multivariate analysis. By ROC curve analysis, time to diagnosis resulted in a poor predictor of outcomes (AUC = 0.27). Since prodromal phase duration was 5 days (IQR 3-7), we divided the cohort into Groups A (1-2 days), B (3-7 days), and C (≥ 8 days). Rates of severe disease were 75.8%, 29.6%, and 11.4%, respectively. Taking Group B as reference, Group A patients had higher risk of complications (p = 0.00001; OR 7.4, 95% CI: 2.98-18.7) while Group C ones had significantly less risk (p = 0.02; OR 0.3, 95% CI: 0.1-0.91). This study found that duration of prodromal phase is an independent predictor of complicated STEC-HUS and confirms that shorter prodromal phase is associated with worse prognosis. A higher resolution version of the Graphical abstract is available as Supplementary information.
Sections du résumé
BACKGROUND
BACKGROUND
Some data have recognized an association between shorter prodromal phase and severe episode of Shiga toxin-producing Escherichia coli-related hemolytic uremic syndrome (STEC-HUS). Our aims were to confirm such association and analyze characteristics of STEC-HUS patients according to duration of the prodromal phase.
METHODS
METHODS
Patients treated from 2000 to 2022 were compared according to the presence of severe (> 10 days of dialysis and/or extra-renal complications) or non-severe disease. Association between prodromal phase duration and disease severity was assessed by ROC curve and by classifying the cohort in 3 groups according to time to diagnosis.
RESULTS
RESULTS
Non-severe (n = 145) and severe (n = 71) cases were compared. The latter had shorter prodromal phase, higher leukocyte count, hemoglobin, lactic dehydrogenase, liver enzymes, C-reactive protein, urea and creatinine, and lower albumin and sodium; only prodromal phase duration (p = 0.02) and leukocyte count (p = 0.02) remained significant in multivariate analysis. By ROC curve analysis, time to diagnosis resulted in a poor predictor of outcomes (AUC = 0.27). Since prodromal phase duration was 5 days (IQR 3-7), we divided the cohort into Groups A (1-2 days), B (3-7 days), and C (≥ 8 days). Rates of severe disease were 75.8%, 29.6%, and 11.4%, respectively. Taking Group B as reference, Group A patients had higher risk of complications (p = 0.00001; OR 7.4, 95% CI: 2.98-18.7) while Group C ones had significantly less risk (p = 0.02; OR 0.3, 95% CI: 0.1-0.91).
CONCLUSIONS
CONCLUSIONS
This study found that duration of prodromal phase is an independent predictor of complicated STEC-HUS and confirms that shorter prodromal phase is associated with worse prognosis. A higher resolution version of the Graphical abstract is available as Supplementary information.
Identifiants
pubmed: 37526769
doi: 10.1007/s00467-023-06104-8
pii: 10.1007/s00467-023-06104-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
213-219Informations de copyright
© 2023. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
Alconcher LF, Coccia PA, Suarez ADC, Monteverde ML, Perez Y, Gutiérrez MG, Carlopio PM, Missoni ML, Balestracci A, Principi I, Ramírez FB, Estrella P, Micelli S, Leroy DC, Quijada NE, Seminara C, Giordano MI, Hidalgo Solís SB, Saurit M, Caminitti A, Arias A, Rivas M, Risso P, Liern M (2018) Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome. Pediatr Nephrol 33:1791–1798. https://doi.org/10.1007/s00467-018-3991-6
doi: 10.1007/s00467-018-3991-6
pubmed: 29961127
Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS (2013) Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 28:2097–2105. https://doi.org/10.1007/s00467-012-2383-6
doi: 10.1007/s00467-012-2383-6
pubmed: 23288350
Wong W, Prestidge C, Dickens A, Ronaldson J (2023) Diarrhoea-associated haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infections in New Zealand children: clinical features and short-term complications from a 23-year cohort study. J Paediatr Child Health 59:493–498. https://doi.org/10.1111/jpc.16332
doi: 10.1111/jpc.16332
pubmed: 36655863
Ardissino G, Daccò V, Testa S, Civitillo CF, Tel F, Possenti I, Belingheri M, Castorina P, Bolsa-Ghiringhelli N, Tedeschi S, Paglialonga F, Salardi S, Consonni D, Zoia E, Salice P, Chidini G (2015) Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome. Pediatr Nephrol 30:345–352. https://doi.org/10.1007/s00467-014-2918-0
doi: 10.1007/s00467-014-2918-0
pubmed: 25149851
Mody RK, Gu W, Griffin PM, Jones TF, Rounds J, Shiferaw B, Tobin-D’Angelo M, Smith G, Spina N, Hurd S, Lathrop S, Palmer A, Boothe E, Luna-Gierke RE, Hoekstra RM (2015) Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. J Pediatr 166:1022–1029. https://doi.org/10.1016/j.jpeds.2014.12.064
doi: 10.1016/j.jpeds.2014.12.064
pubmed: 25661408
Tarr PI (2009) Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura distinct mechanisms of pathogenesis. Kidney Int Suppl 112:29–32. https://doi.org/10.1038/ki.2008.615
doi: 10.1038/ki.2008.615
Eid R, Bakr A, Elmougy A, Zedan MM, Allam NA, Sarhan A, Hammad A, El-Refaey AM, Hamdy N (2020) Postdiarrheal hemolytic uremic syndrome in Egyptian children: an 11-year single-center experience. Saudi J Kidney Dis Transpl 31:1376–1387. https://doi.org/10.4103/1319-2442.308349
doi: 10.4103/1319-2442.308349
pubmed: 33565450
Ardissino G, Tel F, Possenti I, Testa S, Consonni D, Paglialonga F, Salardi S, Borsa-Ghiringhelli N, Salice P, Tedeschi S, Castorina P, Colombo RM, Arghittu M, Daprai L, Monzani A, Tozzoli R, Brigotti M, Torresani E (2016) Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics 137(1). https://doi.org/10.1542/peds.2015-2153
Cobeñas CJ, Lombardi LL, Pereyra P, De Rose E, Gogorza MJ, Spizzirri AP, Ruscasso JD, Ferradas SL, Suárez ÁDC, Amoreo OR, Zalba JH, Risso P (2021) Hypoalbuminemia: a risk factor in patients with STEC-associated hemolytic uremic syndrome. Pediatr Nephrol 36:2739–2746. https://doi.org/10.1007/s00467-021-05017-8
doi: 10.1007/s00467-021-05017-8
pubmed: 33712864
Ninchoji T, Nozu K, Nakanishi K, Horinouchi T, Fujimura J, Yamamura T, Minamikawa S, Ishimori S, Nakanishi K, Yoshikawa N, Morioka I, Kaito H, Iijima K (2017) Clinical characteristics and long-term outcome of diarrhea-associated hemolytic uremic syndrome: a single center experience. Clin Exp Nephrol 21:889–894. https://doi.org/10.1007/s10157-016-1376-3
doi: 10.1007/s10157-016-1376-3
pubmed: 28074307
Ardissino G, Possenti I, Tel F, Testa S, Paglialonga F (2014) Time to change the definition of hemolytic uremic syndrome. Eur J Intern Med 25:e29. https://doi.org/10.1016/j.ejim.2013.12.002
doi: 10.1016/j.ejim.2013.12.002
pubmed: 24360866
Ministerio de Salud de la Nación Argentina. Boletín Integrado de Vigilancia. N° 477 – SE 50 – 2019. https://www.argentina.gob.ar/sites/default/files/201912-biv_477.pdf. Accessed 20 Mar 2023
Ardissino G, Vignati C, Masia C, Capone V, Colombo R, Tel F, Daprai L, Testa S, Dodaro A, Paglialonga F, Luini M, Brigotti M, Picicco D, Baldioli C, Pagani F, Ceruti R, Tommasi P, Possenti I, Cresseri D, Consonni D, Montini G, Arghittu M; ItalKid-HUS Network (2021) Bloody diarrhea and Shiga toxin-producing Escherichia coli hemolytic uremic syndrome in children: data from the ItalKid-HUS network. J Pediatr 237:34-40.e1. https://doi.org/10.1016/j.jpeds.2021.06.048
doi: 10.1016/j.jpeds.2021.06.048
pubmed: 34197890
Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE (2012) Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr Nephrol 27:1407–1410. https://doi.org/10.1007/s00467-012-2158-0
doi: 10.1007/s00467-012-2158-0
pubmed: 22476204
Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE (2014) Laboratory predictors of acute dialysis in hemolytic uremic syndrome. Pediatr Int 56:234–239. https://doi.org/10.1111/ped.12245
doi: 10.1111/ped.12245
pubmed: 24266872
Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, Brun M, Ranchin B, Bandin F, Cloarec S et al (2010) Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5:1218–1228. https://doi.org/10.2215/CJN.08921209
doi: 10.2215/CJN.08921209
pubmed: 20498239
pmcid: 2893076
Rahman RC, Cobeñas CJ, Drut R, Amoreo OR, Ruscasso JD, Spizzirri AP, Suarez Adel C, Zalba JH, Ferrari C, Gatti MC (2012) Hemorrhagic colitis in postdiarrheal hemolytic uremic syndrome: retrospective analysis of 54 children. Pediatr Nephrol 27:229–233. https://doi.org/10.1007/s00467-011-1973-z
doi: 10.1007/s00467-011-1973-z
pubmed: 21809003
Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis (2005) International pediatric sepsis consensus conference defnitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6:2–8
doi: 10.1097/01.PCC.0000149131.72248.E6
pubmed: 15636651
Srinath AI, Lowe ME (2013) Pediatric pancreatitis. Pediatr Rev 34:79–90. https://doi.org/10.1542/pir.34-2-79
doi: 10.1542/pir.34-2-79
pubmed: 23378615
Suri RS, Clark WF, Barrowman N, Mahon JL, Thiessen-Philbrook HR, Rosas-Arellano MP, Zarnke K, Garland JS, Garg AX (2005) Diabetes during diarrhea-associated hemolytic uremic syndrome: a systematic review and meta-analysis. Diabetes Care 28:2556–2562. https://doi.org/10.2337/diacare
doi: 10.2337/diacare
pubmed: 16186301
Ake JA, Jelacic S, Ciol MA, Watkins SL, Murray KF, Christie DL, Klein EJ, Tarr PI (2005) Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 115:e673-680. https://doi.org/10.1542/peds.2004-2236
doi: 10.1542/peds.2004-2236
pubmed: 15930195
Hickey CA, Beattie TJ, Cowieson J, Miyashita Y, Strife CF, Frem JC, Peterson JM, Butani L, Jones DP, Havens PL, Patel HP, Wong CS, Andreoli SP, Rothbaum RJ, Beck AM, Tarr PI (2011) Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 165:884–889. https://doi.org/10.1001/archpediatrics.2011.152
doi: 10.1001/archpediatrics.2011.152
pubmed: 21784993
pmcid: 4064458
Loos S, Oh J, van de Loo L, Kemper MJ, Blohm M, Schild R (2021) Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol 36:3777–3783. https://doi.org/10.1007/s00467-021-05108-6
doi: 10.1007/s00467-021-05108-6
pubmed: 34046736
pmcid: 8497454
Oualha M, Pierrepont S, Krug P, Gitiaux C, Hubert P, Lesage F, Salomon R (2018) Postdiarrheal hemolytic and uremic syndrome with severe multiorgan involvement and associated early risk factors. Arch Pediatr 25:118–125. https://doi.org/10.1016/j.arcped.2017.12.005
doi: 10.1016/j.arcped.2017.12.005
pubmed: 29395881
Luna M, Kamariski M, Principi I, Bocanegra V, Vallés PG (2021) Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage. Pediatr Nephrol 36:1499–1509. https://doi.org/10.1007/s00467-020-04829-4
doi: 10.1007/s00467-020-04829-4
pubmed: 33205220
Shimizu M, Kuroda M, Inoue N, Konishi M, Igarashi N, Taneichi H, Kanegane H, Ito M, Saito S, Yachie A (2014) Extensive serum biomarker analysis in patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine 66:1–6. https://doi.org/10.1016/j.cyto.2013.12.005
doi: 10.1016/j.cyto.2013.12.005
pubmed: 24548418
Kamioka I, Yoshiya K, Satomura K, Kaito H, Fujita T, Iijima K, Nakanishi K, Yoshikawa N, Nozu K, Matsuo M, Japanese Society for Pediatric Nephrology (2008) Risk factors for developing severe clinical course in HUS patients: a national survey in Japan. Pediatr Int 50:441–446. https://doi.org/10.1111/j.1442-200X.2008.02605.x
doi: 10.1111/j.1442-200X.2008.02605.x
pubmed: 19143964